sCD163 level in remission predicts progression of disease within 24 months. Samples were taken when patients were in remission after treatment and values are shown by outcome 24 months later. No patient with low sCD163 in remission relapsed within 24 months. POD24 is calculated from the time of each sample. Intercept line at median value for all patients (3112 ng/mL). POD24, progression of disease within 24 months.